Synovial sarcoma is an aggressive tumor which accounts for almost 10% of all soft tissue sarcomas. In this study, we found the expression of CD133 in human synovial sarcoma specimens, thus we focused on the function of CD133 in synovial sarcoma. Separation of the CD133-positive and -negative subpopulations in synovial sarcoma cell lines clarified that the CD133-negative subpopulation exhibited enhanced growth and hyperphosphorylation of AKT.
Introduction
Synovial sarcoma accounts for almost 10% of all soft tissue sarcomas and typically arises in the para-articular regions in adolescents and young adults. Synovial sarcoma has been shown to be caused by chimeric oncogene product SS18-SSXresulting from chromosomal translocation t(18;X). Synovial sarcoma is a misnomer because its origin is not identical to the synovium [1] . Currently, synovial sarcoma is thought to arise from undifferentiated mesenchymal cells. Prognosis of synovial sarcoma is poor as the 5-and 10-year survival rates are 36% and 20%, respectively [2] .
The precise mechanism of transforming activity of SS18-SSX is not clearly understood.
As SS18 bound to several proteins as chromatin remodeling factor hBRM, histone acetyl transferase p300, or a component of histone deacetylase complex mSin3A, SS18-SSX may disturb epigenetical regulation and this may be contributed to the transforming potential of SS18-SSX [1, 3, 4] . For the malignant potential of invasion or metastasis, tyrosine kinases as Src or Met and its downstream adaptor molecule Crk may be involved [5] [6] [7] .
Stem-like cells in malignant tumors have been shown to be involved in tumor formation, maintenance, chemoresistance, and radiation resistance [8] . In contrast to the extensive research for cancer stem cells in epithelial malignancies as carcinoma such as colon cancer, breast cancer, prostate cancer, etc., only a few studies have been reported for the fields of mesenchymal malignancy as sarcoma [9] [10] [11] . In particular, there are fewer reports investigating whether stem-like cells exist in synovial sarcoma.
Among various stem cell markers, CD133 has been shown to play an important role in various cancers including glioma, prostate cancer, pancreatic cancer, colon cancer, and hepatocellular carcinoma [12] [13] [14] [15] [16] . In addition, epigenetical regulation of CD133 was reported to be involved in glioma [17, 18] . As SS18-SSX may be involved in epigenetical regulations, thus, we investigated the role for CD133, in synovial sarcoma.
Materials and Methods

Cell culture and reagents
The human colon carcinoma cell line Caco-2 and synovial sarcoma cell lines FUJI, HS-SY II, and SYO-1 were cultured in DMEM containing 10% fetal bovine serum (FBS) supplemented with 2 mM L-glutamine, 100 U/ml penicillin G, and 100 g/ml streptomycin, at 37°C (5% CO 2 ). Cells were treated with the AKT inhibitor VIII (Calbiochem, San Diego, CA) at 1.0 μM for 5 days with renewal of media every 24 hours.
Histopathological and immunohistochemical analysis
Five specimens of formalin-fixed, paraffin-embedded human monophasic synovial sarcoma diagnosed in Hokkaido Cancer Center were used under the certification of the ethical committee. The human tumor specimens and the mice xenografts of the cell line in nude mice were sectioned and stained with hematoxylin and eosin (H&E) using standard protocol.
Immunohistochemistry was performed using anti-CD133 (Abcam, Cambridge, UK) antibody.
Semi-quantitative RT-PCR
Total RNA was isolated from synovial sarcoma specimens and all cell lines by using 
SDS-PAGE and immunoblotting
SDS-PAGE and immunoblotting were performed as described previously [19] . 
Xenograft propagation
Subcutaneously, 5 × 10 6 cells were injected with matrigel into three of the 3-week-old female nude mice, BALB/cA Jcl-nu (nu/nu) (CLEA Japan Inc., Japan). The mice were euthanized 22 days after injection, and tumors were removed and weighed. Histopathological examinations were performed.
Results
To For the initial step to evaluate biological differences of CD133-positivity, we examined the expression levels for SS18 interacting proteins such as p300, BRG1, and hBRM in CD133-positive and negative cells, but we could not detect any significant change of these protein levels (Figure 2b ). To examine whether CD133 plays a role for stemness in synovial sarcoma, we confirmed the expression of several mesenchymal stem cell (MSC) markers, which are the candidates for the origin of various sarcomas [9, 11, 20, 21] . However, no significant difference of the levels of MSC markers was observed among CD133-positive/negative subpopulations of synovial sarcoma (Figure 2c ). The levels of SS18-SSX1
were not correlated with the amount of CD133 (Figure 2c ). These data suggest that MSC marker may not be associated with CD133-positive subpopulation in synovial sarcoma cell lines.
To analyze the effect of CD133 on cell proliferation, we analyzed the growth curve of each subpopulation. In both FUJI and SYO-1 cells, growth rate of the CD133-negative population was significantly higher than that of the CD133-positive subpopulation (Figure 3a and 3b). Correlating to these results, the in vivo tumorigenicity of the CD133-positive cells was lower than that of the CD133-negative subpopulations in FUJI and SYO cells (Figure 3c and 3d). Histopathologically, the tumors of all xenografts exhibited the characteristic features of human synovial sarcoma (Figure 3c ). These results indicate that AKT pathway may regulate the growth facilitation of the CD133-negative subpopulation.
Discussion
To elucidate the molecular function of CD133 in synovial sarcoma, we analyzed CD133-positive and -negative subpopulations of synovial sarcoma cell lines and found that CD133-negative subpopulation exhibited high cell proliferation and tumorigenicity associated with AKT hyperphosphorylation. To our knowledge, this is the first report for the analysis of CD133 in synovial sarcoma and the correlation of CD133 to AKT phosphorylation. The observation of phosphorylation of AKT in human synovial sarcoma tissue specimens ensures our data obtained by cell line study. CD133 is serpentine receptor but currently the ligands for CD133 or CD133-dependent signaling pathway is not clearly understood. There is one report that CD133 may enhance tyrosine kinase Src [22] . As we have also found that the levels of Src is altered by CD133 in some condition (data not shown), Src-family tyrosine kinases may be associated with CD133.
In this study, we examined the relationship between CD133 and mesenchymal stem cell (MSC) markers, however, clear correlation is not obtained. MSC is thought to be one of the potential candidates for the origin of various sarcomas [10, 20, 21] . In fact, a few studies have been reported for the sarcoma stem cells in which the stem-like cells of Ewing sarcoma express CD133 and possess MSC features [11, 20, 21] . Our results suggest that the CD133-positive subpopulation in SS cell lines is not significantly associated with features of MSC, and this suggest that origin of synovial sarcoma is different from that of Ewing sarcoma.
Recent report indicating that neural crest cell, which can differentiate both ectoderm and mesoderm, is the potential origin of synovial sarcoma [23] .
The CD133-negative subpopulation has a higher proliferation rate and tumorigenicity in synovial sarcoma cell lines. To date, the relation of cancer stemness and proliferation activity is controversial and it also remains controversial whether CD133 is a bona fide marker for cancer stem cells [24] . While CD133 is widely used as a marker for cancer 
